logo
logo
IMRX stock ticker logo

Immuneering Corporation

NASDAQ•IMRX
CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-07-30
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Contact Information
245 Main Street, Second Floor, Cambridge, MA, 02142, United States
617-500-8080
immuneering.com
Market Cap
$174.25M
P/E (TTM)
-3.8
17.2
Dividend Yield
--
52W High
$10.08
52W Low
$1.10
52W Range
41%
Rank44Top 53.8%
3.7
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.18+0.00%
4-Quarter Trend

FCF

-$9.96M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Decreased Net loss $56.0M for 2025, an 8.2% reduction compared to $61.0M loss reported in 2024.
R&D Spending Reduced Total R&D expenses fell 12.3% to $42.0M in 2025, driven by pausing envometinib program development efforts.
Significant Capital Raised Financing activities provided $226.6M cash, reflecting multiple private placements and public equity offerings during 2025.
Cash Runway Extended Cash reserves $128.6M as of year-end, sufficient to fund operations and development activities into 2029.

Risk Factors

Late-Stage Clinical Dependency Business substantially dependent on successful atebimetinib development; no products approved for commercial sale currently.
Substantial Capital Needs Requires substantial additional capital to finance operations; failure to raise funds delays or eliminates development programs.
Regulatory Approval Unpredictable Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable regarding outcomes for candidates.
Platform Technology Reliance Business substantially dependent on proprietary platform and information technology systems; failure materially harms operations.

Outlook

Phase 3 Trial Dosing Planned Expect dosing first patient in atebimetinib Phase 3 MAPKeeper 301 trial in mid-2026 for pancreatic cancer indication.
Atebimetinib Data Updates Announce further updated survival data from over 50 first-line pancreatic cancer patients in first half of 2026.
New Combination Trial Dosing Dosing first patient in planned atebimetinib combination trial with Libtayo in NSCLC patients second half 2026.
Envometinib Partnership Focus Paused internal advancement of envometinib; pursuing partnership opportunities and considering other developmental paths.

Peer Comparison

Revenue (TTM)

ARCT stock ticker logoARCT
$74.12M
-46.4%
CDXS stock ticker logoCDXS
$70.39M
+18.6%
ENTA stock ticker logoENTA
$66.98M
+0.6%

Gross Margin (Latest Quarter)

ENTA stock ticker logoENTA
100.0%
+0.0pp
ASMB stock ticker logoASMB
100.0%
+0.0pp
SGMO stock ticker logoSGMO
100.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SLS$717.91M-21.1-95.2%1.2%
TRDA$482.00M-3.6-39.8%13.5%
ASMB$451.26M-5.7-59.0%1.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:Mar 19, 2026
|
EPS:-$0.31
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data